BACKGROUND: The mean age of @entity1 starting dialysis increased over the years, as has the proportion of @entity1 with @entity6 , @entity299 , @entity1095 ( @entity1095 ), @entity66 ( @entity66 ) and @entity5 . We assessed dialysis modality choice within subgroups of @entity1 with these comorbidities and in different age categories and subsequently evaluated the association between modality choice and @entity1 survival in these subgroups. METHODS: Seven European renal registries participating in the ERA- @entity1098 Registry provided data from 15,828 incident @entity298 ( @entity298 ) and haemodialysis (HD) @entity1 (1998-2006) with available comorbidity data. The likelihood to receive @entity298 rather than HD was assessed with logistic regression and 3-year survival on @entity298 versus HD was evaluated using Cox regression. RESULTS: Besides large international variations in the likelihood to receive @entity298 , we found that elderly @entity1 and @entity1 with @entity1095 , @entity66 , @entity5 and multiple comorbidities were significantly less likely to receive @entity298 than HD. Overall @entity1 starting on @entity298 had survival benefits [adjusted hazard ratio (HR(adj)) 0.82 (0.75-0.90)], especially @entity1 without comorbidity [HR(adj) 0.65 (0.53-0.80)] or those with @entity5 [HR(adj) 0.73 (0.56-0.94)]. In males, survival benefits of @entity298 were independent of @entity6 status. Conversely, @entity6 females tended to have increased mortality risk on @entity298 [HR(adj) 1.16 (0.93-1.44)], especially if they were >70 years [HR(adj) 1.55 (1.15-2.08)]. CONCLUSIONS: In general, modality choice was consistent with expected survival. However, elderly @entity1 , non- @entity6 @entity1 and those with @entity5 were less likely to receive @entity298 , even though they had decreased mortality risk on @entity298 . Also, although a survival benefit of @entity298 was found for male @entity1 without comorbidity, HD was just as likely to be the chosen dialysis modality as was @entity298 for these @entity1 .

Effects of comorbid and demographic factors on dialysis modality choice and related XXXX survival in Europe.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1095 :: ('MESH:D016491', 'Disease') :: ['PVD', 'peripheral vascular disease'] @entity66 :: ('MESH:D004194', 'Disease') :: ['cerebrovascular disease', 'CD'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes mellitus'] @entity298 :: ('MESH:D010538', 'Disease') :: ['peritoneal dialysis', 'PD'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy'] @entity299 :: ('MESH:D006331', 'Disease') :: ['ischaemic heart disease'] @entity1098 :: ('MESH:D004492', 'Chemical') :: ['EDTA']
@entity1 :: (9606,Species) :: ['patient']
